DOCSLIB.ORG

Sensitivity Analyses of Time to Adjudicated Attacks in the N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sensitivity Analyses of Time to Adjudicated Attacks in the N Sensitivity analyses of time to adjudicated attacks in the N-MOmentum study: P1652 a randomized, placebo-controlled, double-masked trial in patients with neuromyelitis optica spectrum disorder Bruce AC Cree,1 Jeffrey L Bennett,2 Ho Jin Kim,3 Brian Weinshenker,4 Sean J Pittock,4 Dean Wingerchuk,5 Kazuo Fujihara,6 Friedemann Paul,7 Gary Cutter,8 Romain Marignier,9 Ari Green,10 Orhan Aktas,11 Hans-Peter Hartung,11 Fred D Lublin,12 Maureen A Mealy,13 Jorn Drappa,13 Gerard Barron,14 Soraya Madani,13 Dewei She,13 Daniel Cimbora,13 William Rees,13 John N Ratchford13 and Eliezer Katz,13 on behalf of the N-MOmentum Study Investigators 1UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; 2University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, USA; 3Research Institute and Hospital of the National Cancer Center, Seoul, South Korea; 4Mayo Clinic, Rochester, MN, USA; 5Mayo Clinic, Scottsdale, AZ, USA; 6Department of Multiple Sclerosis Therapeutics, Fukushima Medical University and Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Koriyama, Japan; 7Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany; 8University of Alabama at Birmingham, Birmingham, AL, USA; 9Lyon University Hospital, Lyon, France; 10UCSF Weill Institute for Neurosciences, Department of Neurology and Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA; 11Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; 12Icahn School of Medicine at Mount Sinai, New York, NY, USA; 13Viela Bio, Gaithersburg, MD, USA; 14Viela Bio, Cambridge, UK INTRODUCTION Figure 3. Sensitivity and subset analyses for primary variable (time to adjudicated attack; overall population) • Neuromyelitis optica spectrum disorder (NMOSD) is a severe, Number of patients with an attack autoimmune, inflammatory disease of the central nervous system Sensitivitysubset analysis Placebo Inebilizumab HR (95 CI) p value Favours inebilizumab Favours placebo (n 56) (n 174) characterized by repeated attacks of optic neuritis, transverse Number of patients with an attack -determined NMOSD attacs 22 () 21 (121) 22 (1–) 1 myelitis or brain/brainstem encephalitis, which causes disability Sensitivitysubset analysis Placebo Inebilizumab HR (95 CI) p value Favours inebilizumab Favours placebo 1 (primary analysis) or death. (n 56) (n 174) • N-MOmentum is a prospective, randomized, placebo-controlled, nanimous decisions 1 (21) 1 (2) 2 (12–) 1 -determinednvestigator-determined NMOSD attacsattacs 222 (11)() 221 (1)(121) 222 (1–) 1 double-masked trial of inebilizumab, an anti-CD19 monoclonal (primary analysis) 2 atient-reported attacs 2 () (1) (2–) 0.0004 B-cell-depleting antibody, in patients with NMOSD. nanimous decisions 1 (21) 1 (2) 2 (12–) 1 ttacs including patients o 22 () 2 (1) (11–) 2 • In N-MOmentum the risk of an adjudicated NMOSD attack was nvestigator-determinedprematurely discontinued attacs te study 2 (11) 2 (1) 2 (1–) 1 significantly reduced with inebilizumab compared with placebo.2 atient-reportedttacs ased on attacs only clinical criteria 12 () 1 (1) 2 (1–)(2–) 10.0004 ttacsand not includingreuiring patientsM conirmation o 22 () 2 (1) (11–) 2 OBJECTIVE prematurelyomined attacs discontinued or use ote study 2 () 2 (1) 2 (11–) 1 • To assess the robustness of the primary endpoint in N-MOmentum, ttacsrescue terapy ased on only clinical criteria 1 () 1 (1) 2 (1–) 1 and not reuiring M conirmation the time to an adjudicated NMOSD attack, using pre-planned Optic neuritis attacs 1 (1) 1 () 2 (12–) 0.0055 ominedSpinal cord attacs attacs or use o 21 () (2) 21 (1)() 222 (12–)(11–) 0.00051 sensitivity and subset analyses. rescue terapy Optic neuritis attacs 1 (1) 1 () 2 (12–) 0.0055 0.0 0.5 1 1 METHODS Spinal cord attacs 1 (2) 1 () 22 (12–) 0.0005 aard ratio Study design Based on Cox regression method, with placebo as the reference group. AC, adjudication committee; CI, confidence interval; HR, hazard ratio; MRI, magnetic resonance imaging. 0.0 0.5 1 1 Number of patients with an attack • Adults with NMOSD and an Expanded Disability Status Scale aard ratio Placebo Inebilizumab score of ≤ 8 were randomly assigned (3:1) to receive intravenous FigureSensitivitysubset 4. Sensitivity analysis and subset analyses for primary variable (time to HRadjudicated (95 CI) attack; pAQP4-IgG value seropositiveFavours inebilizumab population) Favours placebo (n 52) (n 161) inebilizumab 300 mg or placebo on days 1 and 15, with no other Number of patients with an attack treatments allowed (Figure 1). -determined NMOSD attacs 22 (2) 1 (112) 22 (121–2) 1 Sensitivitysubset(primary analysis) analysis Placebo Inebilizumab HR (95 CI) p value Favours inebilizumab Favours placebo – Participants could be aquaporin 4 (AQP4)-IgG seropositive or (n 52) (n 161) nanimous decisions 1 () 1 () 2 (12–) 1 seronegative. nvestigator-determined-determined NMOSD attacsattacs 222 (2)(2) 221 (1)(112) 2222 (1–)(121–2) 1 • The randomized controlled period was 28 weeks or up to an (primary analysis) atient-reported attacs 2 (1) (1) (2–) 2 adjudicated attack. nanimous decisions 1 () 1 () 2 (12–) 1 ttacs including patients o 22 (2) 22 (1) 2 (12–) 1 – Attacks were evaluated using predefined attack diagnosis prematurelynvestigator-determined discontinued attacs te study 2 (2) 22 (1) 22 (1–) 1 criteria, which were developed specifically for this study. ttacsatient-reported ased on attacs only clinical criteria 12 ()(1) 1 (1)() 21 (2–)(11–) 12 – Each attack was assessed by study investigators and an andttacs not includingreuiring patientsM conirmation o 22 (2) 22 (1) 2 (12–) 1 independent adjudication committee (AC) composed of ominedprematurely attacs discontinued or use ote study 2 (2) 2 (1) 2 (1–) 1 three members. rescuettacs terapy ased on only clinical criteria 1 () 1 () 21 (11–) 1 • Only attacks confirmed by an AC majority (2/3) were used for the Opticand not neuritis reuiring attacs M conirmation 1 (12) () 222 (–) 1 primary endpoint analysis. Spinalomined cord attacs attacs or use o 12 (2)(2) 211 (1)() 212 (–2)(1–) 1 • Sensitivity and subset analyses were performed to assess whether rescue terapy the primary endpoint remained significant when considering Optic neuritis attacs 1 (12) () 222 (–) 1 0.0 0.5 1 1 aard ratio attacks as reported by unanimous AC decisions, by investigators or Spinal cord attacs 1 (2) 11 () 21 (–2) 1 by patients. 0.0 0.5 1 1 • Subsets of the primary endpoint defined by attack type or aard ratio the inclusion of patients who discontinued prematurely were also assessed. Based on Cox regression method, with placebo as the reference group. AC, adjudication committee; AQP4-IgG; aquaporin 4 immunoglobulin G; CI, confidence interval; HR, hazard ratio; MRI, magnetic resonance imaging. Figure 1. N-MOmentum study design RESULTS CONCLUSIONS Day 1 Day 1 300 mg 300 mg • In N-MOmentum, inebilizumab consistently provided a statistically Participants Day 15 Day 15 significant reduction in the risk of attacks compared with placebo, 300 mg Placebo • Of the 467 participants screened, 230 were randomized and dosed, regardless of who evaluated or reported attacks, whether decisions with 175 randomly assigned to inebilizumab (with one patient not were based on only clinical criteria, and also when considering dosed) and 56 to placebo (overall population). individual attack types separately. – In the subset of patients who were AQP4-IgG seropositive, Inebilizumab • These results confirm the robustness of the primary endpoint in the 3 161 were randomized to inebilizumab and 52 to placebo. Open-label N-MOmentum study in both the AQP4-IgG seropositive and the Screening perioda ≥ 1 year • Baseline demographics and characteristics were generally 28 days : RCP – 197 days overall populations. 300 mg inebilizumab Primary endpoint: time to similar between treatment groups in the overall population and in every 6 months 1 NMOSD attack AQP4-IgG seropositive participants. References 1. Cree BAC et al. Mult Scler 2016;22:862–72. Placebo Primary analysis of time to adjudicated attacks 2. Cree BAC et al. Lancet. Forthcoming, September 2019. • According to majority AC decision, 21/174 patients (12.1%) who Acknowledgements Day 15 Day 15 received inebilizumab and 22/56 (39.3%) who received placebo The investigational biological product discussed in this poster (inebilizumab) has not been approved Placebo 300 mg or licensed by the US Food and Drug Administration or by any other regulatory authority, and it is not commercially available in any market. Medical writing support was provided by Oxford PharmaGenesis, experienced attacks. Oxford, UK. This data presentation is sponsored by Viela Bio. Day 1 Day 1 Placebo 300 mg – The risk reduction for inebilizumab versus placebo was 72.8%; hazard ratio, 0.272 (95% confidence interval, 0.150–0.496), Disclosures aPatients eligible for the open-label period at the end of the RCP or after an adjudicated attack. BAC Cree has received personal compensation for consulting from AbbVie, Akili, Alexion, Biogen, N-MOmentum was a double-masked, placebo-controlled study at 99 medical centres in 25 countries, with p < 0.0001 (Figure 2). GeNeuro, EMD Serono, Novartis, Sanofi Genzyme and TG Therapeutics. JL Bennett reports payment a time-to-event design. End of RCP was defined as 67 NMOSD attacks, or when 252 patients had been for study design/consultation from MedImmune/Viela Bio; personal fees from AbbVie, Chugai, Clene randomized and had received study drug, whichever happened first. Enrolment was stopped early at 231 Sensitivity and subset analyses of time to adjudicated attack Nanomedicine, Equillium, Frequency Therapeutics, Genentech, Genzyme and Alexion; grants and patients and 43 attacks due to proven efficacy as determined by the IDMC. No background immunotherapy personal fees from EMD Serono and Novartis; grants from the Guthy–Jackson Charitable Foundation, was permitted. Primary endpoint was the time to NMOSD adjudicated attack within the RCP. Mallinckrodt and the National Institutes of Health; and has a patent for Aquaporumab issued.
Load more

Recommended publications
  • The Scientific Organizing Committee Gratefully Acknowledges the Pharmaceutical and Biotechnology Industry for Their Generous Support of WCBP 2019
    The Scientific Organizing Committee gratefully acknowledges the pharmaceutical and biotechnology industry for their generous support of WCBP 2019: Strategic Diamond Program Partners F. Hoffmann-La Roche Ltd. Genentech, a Member of the Roche Group Strategic Platinum Program Partners Amgen Inc. Biogen MedImmune, A member of the AstraZeneca Group Strategic Gold Program Partners Eli Lilly and Company Merck & Co., Inc. Novo Nordisk A/S Pfizer, Inc. Strategic Silver Program Partner Sanofi 1 Gold Program Partner Bill and Melinda Gates Foundation Silver Program Partners BioMarin Pharmaceutical Inc. Bristol-Myers Squibb Company GlaxoSmithKline Jazz Pharmaceuticals Bronze Program Partner Seattle Genetics, Inc. Friend of CASSS Janssen R&D, LLC 2 The Scientific Organizing Committee gratefully acknowledges the Program Partners and Exhibitors for their generous support of WCBP 2019: Diamond Program Partners Agilent Technologies Catalent Pharma Solutions Eurofins Pharma Discovery Services ProteinSimple, a Bio-Techne brand Thermo Fisher Scientific Waters Corporation Platinum Program Partners BioAnalytix SCIEX Bronze Program Partner Bruker Corporation 3 The Scientific Organizing Committee gratefully acknowledges the Exhibitors for their generous support of WCBP 2019: Exhibitor Partners 908 Devices Inc. NanoImaging Services Agilent Technologies New England Biolabs Associates of Cape Cod, Inc. Postnova Analytics Inc. BioAnalytix Inc. Pressure BioSciences Inc. Bruker Corporation Protein Metrics, Inc. Catalent Pharma Solutions ProteinSimple, a Bio-Techne brand Charles River Laboratories ProZyme, A part of Agilent Covance, Inc. RedShift BioAnalytics, Inc. Cygnus Technologies Rockland Immunochemicals, Inc. Envigo SCIEX Eurofins BioPharma Product Testing SGS Life Science Services Eurofins Pharma Discovery Services Shimadzu Scientific Instruments, Inc. FortéBio - Biologics by Molecular Devices Thermo Fisher Scientific GE Healthcare Life Sciences U.S.
    [Show full text]
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • List of Section 13F Securities, First Quarter, 2014
    List of Section 13F Securities First Quarter FY 2014 Copyright (c) 2014 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2014, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2014. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder.
    [Show full text]
  • Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500
    Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500 www.dyax.com Other Offices Dyax SA, Liege, Belgium ADVANCING NOVEL THERAPEUTIC PRODUCTS Dyax Corp. Annual Report 2003 Corporate Information Dyax Achievements 2003 Dyax Goals 2004 Directors Executive Officers and Stock Listing Henry E. Blair Key Employees Common stock has been traded on the Nasdaq Stock Market Advances in Clinical Development Clinical Development Chairman, President and Henry E. Blair* under the symbol DYAX since our initial public offering in Milestones Chief Executive Officer, Chairman, President and August 14, 2000. DX-88/Hereditary Angioedema Dyax Corp. Chief Executive Officer DX-88/Hereditary Constantine E. Stephen S. Galliker, CPA* The following table gives the quarterly high and low sales G Completed 9-patient Phase II trial, met primary endpoints Angioedema Anagnostopoulos, Ph.D. EVP Finance and prices of our common stock for the last three years. G Genzyme Corporation joined Dyax as joint venture partner Managing General Partner, Administration and G Complete Phase II 2001 2002 2003 G Gateway Associates, LP Chief Financial Officer Completed 3 of 4 dose cohorts in 48-patient Phase II EDEMA1 trial EDEMA1 study High Low High Low High Low G Susan B. Bayh, J.D. Lynn G. Baird, Ph.D.* Initiated Phase II EDEMA2 trial G Periodically observe James W. Fordyce SVP Development First Quarter $20.94 $6.56 $11.38 $3.10 $2.25 $1.52 G Orphan Drug designation granted in U.S. and Europe effects of repeat dosing in Phase II EDEMA2 Managing Partner, Robert C. Ladner, Ph.D. Second Quarter $19.99 $6.81 $ 4.68 $3.20 $4.90 $1.67 Fordyce & Gabrielson, LLC SVP and Chief DX-88/On-Pump Open Heart Surgery (CABG) study Third Quarter $21.24 $6.05 $ 4.20 $1.65 $7.50 $2.58 Mary Ann Gray, Ph.D.
    [Show full text]
  • Saving UK Biotech
    January 22, 2009 Saving UK Biotech Evaluate Vantage While news of the death of the UK biotechnology industry maybe exaggerated, despite a recent spate of companies falling into administration and big pharma picking off some of the best and brightest hopes in the sector, a report into the state of the industry by the Bioscience Innovation and Growth Team published today indicated that an ambulance might be called for unless drastic measures are taken. Chief among the calls from the group, which is supported by the UK’s industry champion, the Biotech Industry Association, was the need for more tax incentives, especially for the pharmaceutical industry to make investments in smaller biotechnology businesses more attractive, in order to ensure the health of the sector. Speedier approvals The National Institute for Health and Clinical Excellence (NICE), which decides on which drugs will be used in the UK’s health service was also identified as a potential barrier to drug innovation, due to the length of time it takes to decide on whether to use drugs. Sir David Cooksey, who was presenting the review on progress made in the industry since 2003, said that the average time between approval of a drug and its introduction by NICE often equated to a third of the patent life of the drug, leaving innovator companies less time to recoup the cost of drug discovery and potentially driving prices up. But the most controversial proposal today was the suggestion that drugs in phase II be used commercially in the UK, whilst waiting for approval, allowing orginators to recoup the cost of development at an earlier stage.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • Public Affairs and Lobbying Register
    Public Affairs and Lobbying Register 3x1 Offices: 16a Walker Street, Edinburgh EH3 7LP 210 Borough High Street, London SE1 1JX 26-28 Exchange Street, Aberdeen, AB11 6PH OFFICE(S) Address: 3x1 Group, 11 Fitzroy Place, Glasgow, G3 7RW Tel: Fax: Web: CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Ailsa Pender Cameron Grant Katrine Pearson Lindsay McGarvie Patrick Hogan LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED Atos North British Distillery Scottish Child Abuse Inquiry SICPA The Scottish Salmon Company Viridor Public Affairs and Lobbying Register Aiken PR OFFICE(S) Address: 418 Lisburn Road, Belfast, BT9 6GN Tel: 028 9066 3000 Fax: 028 9068 3030 Web: www.aikenpr.com CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Claire Aiken Donal O'Neill John McManus Lyn Sheridan Shane Finnegan LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED Diageo McDonald’s Public Affairs and Lobbying Register Airport Operators Associaon OFFICE(S) Address: Airport Operators Association, 3 Birdcage Walk, London, SW1H 9JJ Tel: 020 7799 3171 Fax: 020 7340 0999 Web: www.aoa.org.uk CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Ed Anderson Henk van Klaveren Jeff Bevan Karen Dee Michael Burrell - external public affairs Peter O'Broin advisor Roger Koukkoullis LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED N/A Public Affairs and
    [Show full text]
  • 31 December 2018 Transition and Annual Report 2018
    TRANSITION AND ANNUAL REPORT 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ⌧ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from October 1, 2018 to December 31, 2018 Commission File Number 001-35892 GW PHARMACEUTICALS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Sovereign House, Vision Park Chivers Way, Histon Cambridge, CB24 9BZ United Kingdom +44 1223 266800 (Address of principal executive offices) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing 12 Ordinary The Nasdaq Global Market Shares, par value £0.001 per share Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☑ NO ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES ☐ NO ☑ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • 2019 Scientific Program Committee All Relationships Are Considered Compensated
    2019 Scientific Program Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Patents, Stock and Other Travel, Royalties, Other Expert Other Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Speakers' Bureau Research Funding Accommodations, Intellectual Testimony Relationship Interests Expenses Property Monica M. Leap Syntalogic, Syntimmune Abbvie (Inst), Agenus (Inst), Astellas Pharma (Inst), AstraZeneca Bertagnolli Therapeutics (Inst), Baxalta (Inst), Bayer Health (Inst), Breast Cancer Research Foundation (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Complion (Inst), Eisai (Inst), Exelixis (Inst), Genentech (Inst), GHI Pharma (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Leidos (Inst), Lexicon (Inst), Lilly (Inst), Matrex (Inst), Mayo Clinic (Inst), Merck (Inst), MGH (Inst), Millenium Pharamceuticals (Inst), Novartis (Inst), Patient Centered Outcomes Research Institute (PCORI) (Inst), Pfizer (Inst), Pharmacyclics (Inst), Robert Wood Johnson Foundation (Inst), Sagerock Advisors (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), Tesaro (Inst), Teva (Inst) Suzanne George Abbott Laboratories, AstraZeneca, Bayer, Blueprint ARIAD (Inst), Bayer (Inst), Blueprint Medicines (Inst), Deciphera UptoDate Bayer Research to Abbvie (I), Allergan (I) Medicines, Deciphera, Lilly (Inst), Novartis (Inst), Pfizer (Inst) Practice Melissa
    [Show full text]
  • An Emerging National Resource for Clinical Research and Your Healthcare Partner in Personalized Medicine Innovation
    An Exclusive Membership Look into Colorado To visualize improving the world around us Fisher Scientifi c, part of Thermo Fisher Scientifi c, the world leader in serving science, is pleased to have the opportunity to partner with the Colorado BioScience Association and act as primary supplier of laboratory products, safety supplies, equipment, chemicals, reagents and a host of services. Fisher Scientifi c understands today’s challenging environment and has capabilities that align with CBSA’s strategic goals going beyond just providing products to o ering Colorado BioScience Association members access to customized programs to fi t their specifi c needs from start-up to scale-up. 1.800.766.7000 • Fax: 1.800.926.1166 • www.fi shersci.com 2 BIOSCIENCECOLORADO 2014-2015 Litho in U.S.A. 13_0280 JJ/KJ COLOR ADO 2014-2015 Drawing People & Data Together to Benefit Human Health 10 22 26 14 6 CONTENTS 06 Mobile Health in Colorado: Where “Big Data” Sparks Big Ideas 10 Biodesix Harnesses Machine Learning and Analytics to Tackle Multivariate Diagnostics 14 Bioscience in Colorado Continues to Shine with U.S. Senator Michael Bennet 16 Color ado Life Science Assets: A Sophisticated Repertoire of Clinical-Stage Therapeutic, Device and Diagnostic Products 22 Webb-Waring Biomedical Research Program 26 F ound in Translation: Rocky Mountain Lions Eye Institute Translational Research Programs Focus on Innovative Treatment of Eye Diseases 30 Connecting the Dots: Tech Transfer Offices Connect Research and Marketplace to Stimulate the State's Economy 33 Colorado by the Numbers: Financing and Acquisitions 36 Grant Programs: Innovation Engines 48 Colorado Bioscience Industry Directory 2014-2015 BIOSCIENCECOLORADO 3 We Know Workforce elcome to the Colorado BioScience Association’s eleventh anniversary edition of Bioscience Colorado.
    [Show full text]